2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

La Merie Publishing released on March 15, 2022 the 16th edition of the report series about sales of Blockbuster Biologics. This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 17, 2021. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases as constant exchange rates).

2021 sales data of biosimilar antibodies and proteins are included in the report provided that the data were published by the companies. This report also includes sales data of new biologic modalities such as gene and cell therapy and RNAi.

Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins.

Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies.

Development of sales of the growing drug modality of antibody-drug conjugates are also presented.

A total of 69 biologic therapeutics reached blockbuster status with 2021 sales exceeding US$ 1 bln. Sales of 14 new antibody and protein products for the year 2021 were included for the first time in this report. Antibody sales represented more than 75% of total biologics sales in 2020. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2021 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2021.

See also our related product Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscription which provides online access to our database plus a hard copy in pdf format of this report.